Bisphosphonate osteonecrosis of the jaw - A literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention

British Journal of Oral and Maxillofacial Surgery

Volumn 49, Issue 4, 2011, Pages 251-257

  Patel, Vinod ^a   McLeod, Niall M H ^b   Rogers, Simon N ^c   Brennan, Peter A ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Bisphosphonate; Jaw bone; Osteonecrosis; Prevention; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

AGE DISTRIBUTION; ANEMIA; BIPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW; DENTAL SURGERY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; GASTROINTESTINAL DISEASE; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; MEDICAL SOCIETY; MOUTH HYGIENE; MOUTH INFECTION; MOUTH INJURY; OBESITY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; SMOKING; TREATMENT DURATION;

EID: 79957856250     PISSN: 02664356     EISSN: 15321940     Source Type: Journal    
DOI: 10.1016/j.bjoms.2010.05.007     Document Type: Article

References (67)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. (Pubitemid 37064711)
2. Sambrook P, Olver I, Goss A. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006;35:801-3.
3. Australian Dental Association Public Statement. Bisphosphonates - team work required. 2007. Available from URL: http://www.ada.org.au/newsroom/article, documentid,109063.aspx.
4. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the Jaws. J Oral Maxillofac Surg 2007;65:369-76.
5. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009;67:2-12.
6. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35:1391-7 [Erratum in: J Rheumatol 2008; 35:2084, J Rheumatol 2008; 35:1688].
7. Sambrook PN. Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw. Nat Clin Pract Rheumatol 2009;5:6-7.
8. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
9. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-7 [Erratum in: J Am Dent Assoc 2009;140:522].
10. Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 2007;12:E336-40.
11. American Association of Endodontists Position Statement. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws; 2006. Available from URL: http://www.aae.org/dentalpro/guidelines.htm.
12. American Association of Endodontists newsletter. Bisphosphonate- associated osteonecrosis of the jaw;Winter 2007. Available from URL: http://www.aae.org/dentalpro/ClinicalNewsletters/.
13. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68. (Pubitemid 41810027)
14. Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 2009;71:12-21.
15. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. (Pubitemid 351229318)
16. British Dental Association. Bisphosphonates. Fact file. British Dental Association; 2008. Available from URL: http://www.bda.org.
17. McLeod NM, Davies BJ, Brennan PA. Bisphosphonate osteonecrosis of the jaws; an increasing problem for dental practitioner. Br Dent J 2007;203:641-4.
18. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008;98:1736-40. (Pubitemid 351748847)
19. Hohnecker JA. Novartis "Dear Doctor" precautions added to label of Aredia and Zometa. September 24, 2004. Available from URL: http://www.fda.gov.
20. Cheng A, Mavrokokki A, Carter G, Stein B, Fazzalari NL, Wilson DF, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50(4 Suppl. 2):S4-13.
21. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. (Pubitemid 46211499)
22. Krauth MT, Fügl A, Gruber R. (Bisphosphonate-associated osteonecrosis of the jaw). Wien Klin Wochenschr 2008;120:467-76 [in German].
23. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5. (Pubitemid 46465699)
24. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-31. (Pubitemid 351381804)
25. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18:2015-9. (Pubitemid 350286242)
26. Arrain Y, Masud T. Recent recommendations on bisphosphonate-associated osteonecrosis of the jaw. Dent Update 2008;35: 238-40, 242.
27. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52. (Pubitemid 46638849)
28. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73:417-22.
29. Rayman S, Almas K, Dincer E. Bisphosphonate-related jaw necrosis: a team approach management and prevention. Int J Dent Hyg 2009;7:90-5.
30. Malden NJ, Pai AY. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J 2007;203:93-7.
31. Takagi Y, Sumi Y, Harada A. Osteonecrosis associated with short-term oral administration of bisphosphonate. J Prosthet Dent 2009;101:289-92.
32. Conte P. Optimizing bisphosphonate therapy in oncology. The Oncologist 2004;9:1-2. Available from URL: http://theoncologist.alphamedpress.org/cgi/ content/full/9/suppl 4/1.
33. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Res Ther 2006;8:219.
34. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005;17:462-6. (Pubitemid 41058407)
35. Mehrotra B. Bisphosphonates-role in cancer therapies. J Oral Maxillofac Surg 2009;67(5 Suppl.):19-26.
36. Kunchur R, Goss AN. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 2008;53:354-7.
37. Carvalho A, Amaral Mendes R, Carvalho D, Carvalho JF. (Osteonecrosis of the mandible induced by intravenous bisphosphonates in oncological patients). Acta Med Port 2008;21:505-10 [in Portuguese].
38. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-20.
39. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45.
40. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.
41. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jawsurgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23.
42. Magremanne M. (Osteoporosis, bisphosphonates and jaws osteochemonecrosis). Rev Med Brux 2008;29:262-6 [in French].
43. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-8.
44. Marx RE, Cillo Jr JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. (Pubitemid 350100982)
45. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of Cterminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:1167-73.
46. American Society for Bone and Mineral Research Task force on osteonecrosis of the jaw. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008;66:1320-2 [Erratum in: J Oral Maxillofac Surg 2008;66:1778].
47. Don-Wauchope AC, Cole DE. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clin Biochem 2009;42:1194-6.
48. Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009;15:88-92.
49. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT /CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med 2009;50:30-5.
50. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:249-58.
51. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006;35:236-43. (Pubitemid 44076879)
52. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-64.
53. Kwon YD, Kim YR, Choi BJ, Lee DW, Kim DY. Oral bisphosphonaterelated osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int 2009;40:277-8.
54. Gallego L, Junquera L. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg 2009;47:67-8.
55. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61 [Erratum in: Ann Intern Med 2006;145:235].
56. Assael LA. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks and preventive strategies. J Oral Maxillofac Surg 2009;67(5 Suppl.):35-43.
57. Serra MP, Llorca CS, Donat FJ. Oral implants in patients receiving bisphosphonates: a review and update. Med Oral Patol Oral Cir Bucal 2008;13:E755-60.
58. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66:223-30.
59. Ren YF, Malmstrom HS. Effectiveness of antibiotic prophylaxis in third molar surgery: a meta-analysis of randomized controlled clinical trials. J Oral Maxillofac Surg 2007;65:1909-21. (Pubitemid 47404728)
60. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008;49:2156-62.
61. McLeod NM, Davies BJ, Brennan PA. Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK. Surgeon 2009;7:18-23.
62. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47. (Pubitemid 351522817)
63. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm. Br Dent J 2009;206:93-8.
64. Laskin DM. The use of prophylactic antibiotics for the prevention of postoperative infections. Oral Maxillofac Surg Clin North Am 2003;15:155-60. (Pubitemid 36416657)
65. Caso A, Hung L, Beirne OR. Prevention of alveolar osteitis with chlorhexidene: a meta-analytic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:155-9. (Pubitemid 40127189)
66. Hermesch CB, Hilton TJ, Biesbrock AR, Baker RA, Cain-Hamlin J, McClanahan SF, et al. Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: efficacy and risk factor analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:381-7. (Pubitemid 128645213)
67. Rejev E, Lustmann J, Nashef R. Atraumatic teeth extraction in bisphosphonate-treated patients. J Oral Maxillofac Surg 2008;66:1157-61. (Pubitemid 351671952)